Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed 32, 2020.
   Google Scholar
• RodrigoGJ, PriceD, AnzuetoA, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD.S13048228360514
   PubMed Web of Science ®Google Scholar
• HoritaN, GotoA, ShibataY, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066.28185242
   PubMed Web of Science ®Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• VogelmeierC, PaggiaroPL, DorcaJ, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a Phase 3 COPD study. Eur Respir J. 2016;48(4):1030–1039. doi:10.1183/13993003.00216-201627492833
   PubMed Web of Science ®Google Scholar
• DonohueJF, WorsleyS, ZhuCQ, HardakerL, ChurchA. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881. doi:10.1016/j.rmed.2015.04.01826006754
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, BatemanED, PallanteJ, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2016;48(4):51–60. doi:10.1016/S2213-2600(12)70052-8
   Web of Science ®Google Scholar
• KewKM, SeniukovichA. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
   PubMed Web of Science ®Google Scholar
• SuissaS, PatenaudeV, LapiF, ErnstP. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. doi:10.1136/thoraxjnl-2012-20287224130228
   PubMed Web of Science ®Google Scholar
• NanniniLJ, LassersonTJ, PooleP. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• WallaceAE, KailaS, BayerV, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25(2):205–217.30698096
   PubMed Web of Science ®Google Scholar
• RestrepoRD, AlvarezMT, WittnebelLD, et al. Medication adherence issues in patients treated for COPD. Int J COPD. 2008;3(3):371–384. doi:10.2147/COPD.S3036
   Google Scholar
• ManninoDM, YuT-C, ZhouH, HiguchiK. Effects of GOLD-adherent prescribing on COPD symptom burden, exacerbations, and health care utilization in a real-world setting. COPD. 2015;2(3):223–235. doi:10.15326/jcopdf.2.3.2014.015128848845
   PubMedGoogle Scholar
• MoretzC, SharpstenL, BengtsonLG, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737. doi:10.2147/COPD.S20464931534326
   PubMed Web of Science ®Google Scholar
• DillmanDA, SmythJD, ChristianLM. Internet, Mail, and Mixed-Mode Surveys: The Tailored Design Method. 4th ed. Hoboken, New Jersey: John Wiley & Sons, Inc; 2014.
   Google Scholar
• JonesPW, HardingG, BerryP, WiklundI, ChenWH, Kline LeidyN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• JonesPW, AdamekL, NadeauG, BanikN. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013;42(3):647–654. doi:10.1183/09031936.0012561223258783
   PubMed Web of Science ®Google Scholar
• JonesPW, BrusselleG, Dal NegroRW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38(1):29–35. doi:10.1183/09031936.0017721021565915
   PubMed Web of Science ®Google Scholar
• The American Association for Public Opinion Research. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. Deerfield, IL: AAPOR; 2016 Available from: http://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf. Accessed 32, 2020.
   Google Scholar
• RayR, HahnB, StanfordRH, WhiteJ, EssoiB, HunterAG. Classification of patients with COPD on LAMA monotherapy using the GOLD criteria: analysis of a claims-linked patient survey study. Pulmonary Ther. 2019;5(2):191–200. doi:10.1007/s41030-019-00099-032026409
   PubMedGoogle Scholar
• PriceDB, BakerCL, ZouKH, HigginsVS, BaileyJT, PikeJS. Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. Int J Chron Obstruct Pulmon Dis. 2014;9:551–561.24920893
   PubMed Web of Science ®Google Scholar
• PriceD, WestD, BrusselleG, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S6275025210450
   PubMed Web of Science ®Google Scholar